Advanced Biomedical Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$2,464	1
2023	Research	$1,114	3
2021	Research	$182,174	21
2020	Research	$304,931	20
2019	Research	$441,612	49

Breakdown

Who paid Research payments · program years 2019–2024

AbbVie, Inc. $834,732 57 payments
Shire North American Group Inc $44,500 15 payments
Allergan Inc. $36,791 9 payments
Ironwood Pharmaceuticals, Inc $9,545 3 payments
AstraZeneca Pharmaceuticals LP $5,698 5 payments
E.R. Squibb & Sons, L.L.C. $837 1 payment
Pfizer Inc. $192 4 payments

Studies the money was for Research payments · program years 2019–2024

M16-100 $590,297 33 payments
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $137,402 11 payments
M19-161 $65,217 5 payments
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain $16,500 3 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) $13,500 2 payments
A 52-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active- Controlled, Operationally Seamless Phase 2B3, Parallel-Group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohns Disease $12,801 2 payments
24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy $11,816 3 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $11,052 4 payments
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $10,000 1 payment
McP-103-205 $9,545 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.